South America Dermatological Drugs Market Outlook, 2031

2026

South America Dermatological Drugs Market Outlook, 2031

The South America Dermatological Drugs Market is segmented into By Indication (Acne, Psoriasis, Atopic Dermatitis, Rosacea, Alopecia, Skin Cancer, Others), By Drug Class / Molecule Type (Corticosteroids, Biologics, Retinoids, Anti-infectives, Calcineurin Inhibitors, Others), By Route of Administration (Topical, Oral, Injectable / Parenteral), By Drug Type (Prescription-based Drugs, Over-the-Counter (OTC) Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies).

Bonafide Research
04-07-2026
Pages : 82
Figures : 6
Tables : 25
Region : South America
Category : Lifescience & Healthcare
Pharmaceutical

Schedule a Call

Buy Now Get Free sample

The South America Dermatological Drugs market is expected to reach USD 2.61 billion by 2031, supported by improving healthcare access and growing dermatology demand.

Historical Period2020-2024
Base Year2025
Forecast Period2026-2031
Market Size (2031) USD 2.61 Billion
Largest Market Brazil
Fastest Market Colombia
Format

Featured Companies

1. Pfizer Inc.
2. Sanofi S.A.
3. AbbVie Inc.
4. Bausch Health Companies Inc.
5. Inmode Ltd
6. Haleon plc
More...

Highend Report

Highend report of this product is available

View

New Report Guarantee

If you purchase this report now and we update it in next 100 days, get it free!

Dermatological Drugs Market Analysis

The South American dermatological drugs market represents an emerging frontier in global pharmaceutical expansion, characterized by rapidly evolving regulatory frameworks, substantial disease burden, and increasing healthcare accessibility across the continent. Over the past five years, this market has undergone significant transformation, transitioning from a predominantly generic-driven landscape to one increasingly embracing innovative biologics, targeted topical therapies, and JAK inhibitors, driven by regulatory modernization across major economies. The clinical management of complex, life-threatening skin conditions like Generalized Pustular Psoriasis (GPP) which has an estimated public-sector prevalence of 0.89 per 100,000 individuals in Brazil is undergoing a significant transition. Hidradenitis suppurativa is estimated at 0.3% to 0.5%, while alopecia areata lifetime risk approximates 1% to 2%. Brazil serves as the largest national market within the region, accounting for a significant share of dermatological drug sales. The National Health Surveillance Agency in Brazil has accelerated approvals for innovative dermatological therapies, granting marketing authorization for Winlevi (clascoterone) cream 1% for acne vulgaris in patients aged twelve years and older. Argentina's ANMAT has implemented sweeping regulatory reforms through Disposition 236/2026, simplifying import requirements for medical products and cosmetics. These regulatory advancements, coupled with rising disease awareness and expanding healthcare infrastructure, continue to reshape dermatological care across South America. The market's clinical directives and regulatory pathways are guided by the Asociación Colombiana de Dermatología y Cirugía Dermatológica (Asocolderma) and the National Institute for Drug and Food Surveillance (INVIMA), while commercial supply chains are driven by key entities including Eurofarma Colombia, Galderma, Sanofi, Novartis, Tecnoquímicas, and Procaps. According to the research report, "South America Dermatological Drugs Market Outlook, 2031," published by Bonafide Research, the South America Dermatological Drugs market is expected to reach a market size of USD 2.61 Billion by 2031. Argentina, with a current market size of USD 164.46 million, continues to contribute steadily to regional growth, driven by gradual improvements in healthcare infrastructure and rising awareness of dermatological care. Colombia is also anticipated to be one of the fastest-growing markets in South America, with its dermatological drugs market forecast to reach USD 230.59 million by 2031, supported by increasing healthcare access, expanding treatment adoption, and growing investment in specialty pharmaceuticals across the country. Growth in the region is being driven by rising awareness of skin health, increasing prevalence of dermatological conditions, improving access to healthcare services, and expanding adoption of advanced dermatological treatments across both urban and semi-urban populations. Cosmo Pharmaceuticals has strengthened its South American presence following ANVISA's approval of Winlevi (clascoterone) cream 1% for acne vulgaris treatment in patients aged twelve years and older. The Brazilian dermatological drugs market demonstrated dynamic double-digit value growth throughout 2025, driven by strong performance in nappy rash treatments and increasing allergy incidences across the population. Argentina's ANMAT has implemented transformative regulatory reforms under Disposition 236/2026, establishing a simplified affidavit-based authorization system for imported medical products and cosmetics, eliminating expiration dates and reducing administrative requirements. Chile's Institute of Public Health has intensified enforcement actions, canceling sanitary registrations for unauthorized cosmetic products and issuing alerts regarding illegal injection of cosmetic products in dermatology clinics. Colombia's INVIMA issued Resolution 2025029237, adopting a pro-competitive regulatory model aimed at transforming health procedure management.

to Download this information in a PDF

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample

Market Dynamics

Market Drivers• Regulatory Modernization: South American regulatory authorities have dramatically accelerated dermatological drug approvals and market access. Brazil's ANVISA granted marketing authorization for Winlevi (clascoterone) cream 1% for acne vulgaris in 2025, while Argentina's ANMAT implemented Disposition 236/2026 simplifying import requirements. Colombia's INVIMA adopted a pro-competitive regulatory model through Resolution 2025029237. These progressive reforms drive market expansion across the region.
• Rising Disease Burden: South America bears a substantial and growing burden of dermatological conditions requiring advanced therapeutics. The Brazilian Society of Dermatology reports psoriasis affects approximately 1.3% of Brazil's population. Atopic dermatitis affects 2% to 3% of adults across Latin America, with Brazil demonstrating the highest prevalence among Latin American countries at 20.1%. This immense patient population creates sustained demand for dermatological therapeutics.

Market Challenges• Regulatory Complexity and Fragmentation: South America presents a complex regulatory landscape with significant variations between ANVISA in Brazil, ANMAT in Argentina, ISP in Chile, and INVIMA in Colombia. Each agency maintains distinct requirements for clinical evidence, manufacturing standards, and post-marketing surveillance. ANVISA requires comprehensive product registration and labeling in Brazilian Portuguese. This fragmentation creates substantial barriers for pharmaceutical companies seeking regional market access.
• Healthcare Access Disparities: Significant disparities in healthcare access and treatment affordability persist across South American nations. Chile's ISP has intensified enforcement actions, canceling sanitary registrations for unauthorized products. Limited dermatologist availability in rural areas constrains patient access to prescription therapies. These barriers limit patient access to advanced dermatological treatments across emerging South American markets, particularly affecting underserved populations.

Market Trends• Innovative Topical Therapy Expansion: Novel topical therapies are gaining significant momentum across South American dermatology. ANVISA approved Winlevi (clascoterone) cream 1% for acne vulgaris in patients aged twelve years and older. ANVISA has also expanded regulatory frameworks to permit registration of dermatological cannabis-based products. These developments reflect growing clinical acceptance of innovative topical therapies across multiple dermatological indications.
• Regulatory Efficiency Reform: South American regulatory authorities are implementing sweeping reforms to accelerate market access. Argentina's ANMAT established a simplified affidavit-based authorization system under Disposition 236/2026, eliminating expiration dates and reducing requirements. Colombia's INVIMA adopted a pro-competitive regulatory model through Resolution 2025029237. These reforms streamline approval processes and reduce time-to-market for dermatological products.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Kavita Mehra

Business Development Manager

Dermatological Drugs Segmentation

By Indication	Acne
	Psoriasis
	Atopic Dermatitis
	Rosacea
	Alopecia
	Skin Cancer
	Others
By Drug Class / Molecule Type	Corticosteroids
	Biologics
	Retinoids
	Anti-infectives
	Calcineurin Inhibitors
	Others
By Route of Administration	Topical
	Oral
	Injectable / Parenteral
By Drug Type	Prescription-based Drugs
	Over-the-Counter (OTC) Drugs
South America	Brazil
	Argentina
	Colombia

Psoriasis dominates the South American dermatological drugs market due to its substantial prevalence across the region and high proportion of patients requiring systemic therapy. Psoriasis represents the largest indication in the South American dermatological drugs market, driven by the immense patient population across the continent. The Brazilian Society of Dermatology reports that psoriasis affects approximately 1.3% of Brazil's population, with prevalence varying from 0.9% to 1.1% in the Northern region to 1.9% in the South and Southeast. Psoriasis prevalence in Latin America ranges from 0.5% to 2%. The condition affects approximately 3 million Brazilians. Psoriasis can emerge at any age, with peak onset between 30 and 60 years. The chronic, systemic nature of psoriasis necessitates long-term treatment, driving sustained prescription volumes. Increasing awareness and earlier diagnosis across the region continue to expand the addressable patient population. The availability of biologic therapies and targeted treatments has expanded options for moderate-to-severe cases. The rising prevalence of autoimmune triggers sustains market growth across South America. Calcineurin inhibitors are experiencing rapid growth across South America driven by their steroid-sparing properties and expanding approval for pediatric atopic dermatitis. Calcineurin inhibitors have emerged as the fastest-growing drug class in the South American dermatological drugs market, driven by their unique mechanism of action and favorable safety profile. These agents offer effective steroid-sparing alternatives for managing atopic dermatitis, addressing significant unmet needs across the region. Atopic dermatitis affects 2% to 3% of adults across Latin America. Brazil demonstrates the highest prevalence of atopic dermatitis among Latin American countries at 20.1%. The class addresses steroid phobia a significant barrier to treatment adherence reported across South American markets. Calcineurin inhibitors are particularly valuable for treating sensitive areas including the face and intertriginous regions. The rising prevalence of atopic dermatitis across South America drives sustained demand. These therapies offer favorable safety profiles for long-term use in pediatric populations. The expanding therapeutic indications for calcineurin inhibitors across multiple dermatological conditions continue to drive market growth. Topical administration maintains market leadership across South America due to patient preference for non-invasive therapy and the substantial burden of mild-to-moderate skin conditions. Topical administration represents the largest route of administration in the South American dermatological drugs market, driven by the high prevalence of mild-to-moderate skin conditions amenable to localized therapy. Topical therapies offer targeted delivery to affected areas, minimizing systemic exposure and side effects. Patient preference for non-invasive, self-administered treatments drives topical product adoption across the region. The availability of diverse topical formulations provides therapeutic options for various skin types and conditions. ANVISA approved Winlevi (clascoterone) cream 1% for acne vulgaris, expanding topical treatment options. Topical therapies are particularly valuable in regions with limited healthcare infrastructure, enabling accessible treatment. The rising prevalence of atopic dermatitis, psoriasis, and acne across South America sustains demand for topical products. The development of novel topical formulations with enhanced penetration continues to expand the therapeutic arsenal. Over-the-counter dermatological drugs are experiencing moderate growth across South America driven by increasing self-medication trends and expanding retail pharmacy networks. Over-the-counter dermatological drugs represent a moderately growing segment in the South American market, driven by consumer preference for accessible, affordable self-care options. OTC products address mild skin conditions including acne, dermatitis, and fungal infections without requiring physician consultation. The expansion of retail pharmacy networks has improved OTC product accessibility across the region. Rising consumer awareness of skin health and preventive care drives OTC product adoption. OTC dermatologicals offer affordable treatment options for price-sensitive consumers across emerging South American markets. Brazil's dermocosmetics market generated R$12.3 billion in the twelve months ending July 2025, representing 8.3% growth. The availability of established OTC brands supports moderate market growth. However, growth is constrained by the limited therapeutic scope of OTC products compared to prescription alternatives for moderate-to-severe conditions. Online pharmacies are experiencing explosive growth across South America driven by digital health adoption, convenience, and expanding e-commerce infrastructure. Online pharmacies represent the fastest-growing distribution channel in the South American dermatological drugs market, driven by the region's rapid digital transformation and consumer preference for convenient healthcare access. The COVID-19 pandemic accelerated digital health adoption across the region, normalizing online pharmacy usage. Online platforms offer competitive pricing and home delivery, addressing accessibility challenges in remote areas. The integration of telemedicine with online pharmacy services enables seamless prescription fulfillment. Rising smartphone penetration and internet connectivity across emerging South American markets support online pharmacy growth. Consumer preference for discreet purchasing of dermatological products drives online channel adoption. Regulatory frameworks across the region are evolving to accommodate and regulate online pharmaceutical distribution. Online platforms are expected to significantly reshape distribution dynamics in the coming years.

to Download this information in a PDF

Dermatological Drugs Market Regional Insights

Brazil dominates the South American dermatological drugs market through its massive population, sophisticated regulatory framework, and expanding pharmaceutical innovation ecosystem. Brazil is expected to remain the largest market in the region, registering a CAGR of 7.54% during the forecast period, supported by its large population base, strong pharmaceutical industry presence, and growing demand for both prescription and over-the-counter dermatology drugs. Brazilian Society of Dermatology reports that psoriasis affects approximately 1.3% of the population, affecting millions of Brazilians. ANVISA has accelerated dermatological drug approvals, granting marketing authorization for Winlevi (clascoterone) cream 1% for acne vulgaris and expanding regulatory frameworks for dermatological cannabis-based products. The Brazilian dermatological drugs market demonstrated dynamic double-digit value growth throughout 2025. Brazil's dermocosmetics market generated R$12.3 billion in the twelve months ending July 2025. Favorable government policies support pharmaceutical innovation and market access. Retail pharmacy expansions with digital health integration add lucrative growth opportunities. The large number of individuals seeking affordable treatments fuels sustained market expansion across Brazil. The country's sophisticated regulatory framework provides a structured environment for pharmaceutical market entry.

to Download this information in a PDF

Don't pay for what you don't need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now

Companies Mentioned

Pfizer Inc.
Sanofi S.A.
AbbVie Inc.
Bausch Health Companies Inc.
Inmode Ltd
Haleon plc
Almirall, S.A.
LEO Pharma A/S

1. Executive Summary
2. Market Dynamics
2.1. Market Drivers & Opportunities
2.2. Market Restraints & Challenges
2.3. Market Trends
2.4. Supply chain Analysis
2.5. Policy & Regulatory Framework
2.6. Industry Experts Views
3. Research Methodology
3.1. Secondary Research
3.2. Primary Data Collection
3.3. Market Formation & Validation
3.4. Report Writing, Quality Check & Delivery
4. Market Structure
4.1. Market Considerate
4.2. Assumptions
4.3. Limitations
4.4. Abbreviations
4.5. Sources
4.6. Definitions
5. Economic /Demographic Snapshot
6. South America Dermatogical Drug Market Outlook
6.1. Market Size By Value
6.2. Market Share By Country
6.3. Market Size and Forecast, By Indication
6.4. Market Size and Forecast, By Drug Class / Molecule Type
6.5. Market Size and Forecast, By Route of Administration
6.6. Market Size and Forecast, By Drug Type
6.7. Market Size and Forecast, By Distribution channel
6.8. Brazil Dermatogical Drug Market Outlook
6.8.1. Market Size by Value
6.8.2. Market Size and Forecast By Indication
6.8.3. Market Size and Forecast By Drug Class / Molecule Type
6.8.4. Market Size and Forecast By Route of Administration
6.8.5. Market Size and Forecast By Drug Type
6.8.6. Market Size and Forecast By Distribution channel
6.9. Argentina Dermatogical Drug Market Outlook
6.9.1. Market Size by Value
6.9.2. Market Size and Forecast By Indication
6.9.3. Market Size and Forecast By Drug Class / Molecule Type
6.9.4. Market Size and Forecast By Route of Administration
6.9.5. Market Size and Forecast By Drug Type
6.9.6. Market Size and Forecast By Distribution channel
6.10. Colombia Dermatogical Drug Market Outlook
6.10.1. Market Size by Value
6.10.2. Market Size and Forecast By Indication
6.10.3. Market Size and Forecast By Drug Class / Molecule Type
6.10.4. Market Size and Forecast By Route of Administration
6.10.5. Market Size and Forecast By Drug Type
6.10.6. Market Size and Forecast By Distribution channel
7. Competitive Landscape
7.1. Competitive Dashboard
7.2. Business Strategies Adopted by Key Players
7.3. Porter's Five Forces
7.4. Company Profile
7.4.1. Galderma S.A.
7.4.1.1. Company Snapshot
7.4.1.2. Company Overview
7.4.1.3. Financial Highlights
7.4.1.4. Geographic Insights
7.4.1.5. Business Segment & Performance
7.4.1.6. Product Portfolio
7.4.1.7. Key Executives
7.4.1.8. Strategic Moves & Developments
7.4.2. LEO Pharma A/S
7.4.3. Almirall, S.A.
7.4.4. Bausch Health Companies Inc.
7.4.5. Haleon plc
7.4.6. AbbVie Inc.
7.4.7. Sanofi S.A.
7.4.8. Pfizer Inc.
8. Strategic Recommendations
9. Annexure
9.1. FAQ`s
9.2. Notes
10. Disclaimer

Table 1: Influencing Factors for Dermatogical Drug Market, 2025
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: South America Dermatogical Drug Market Size and Forecast, By Indication (2020 to 2031F) (In USD Billion)
Table 6: South America Dermatogical Drug Market Size and Forecast, By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 7: South America Dermatogical Drug Market Size and Forecast, By Route of Administration (2020 to 2031F) (In USD Billion)
Table 8: South America Dermatogical Drug Market Size and Forecast, By Drug Type (2020 to 2031F) (In USD Billion)
Table 9: South America Dermatogical Drug Market Size and Forecast, By Distribution channel (2020 to 2031F) (In USD Billion)
Table 10: Brazil Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 11: Brazil Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 12: Brazil Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 13: Brazil Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 14: Brazil Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 15: Argentina Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 16: Argentina Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 17: Argentina Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 18: Argentina Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 19: Argentina Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 20: Colombia Dermatogical Drug Market Size and Forecast By Indication (2020 to 2031F) (In USD Billion)
Table 21: Colombia Dermatogical Drug Market Size and Forecast By Drug Class / Molecule Type (2020 to 2031F) (In USD Billion)
Table 22: Colombia Dermatogical Drug Market Size and Forecast By Route of Administration (2020 to 2031F) (In USD Billion)
Table 23: Colombia Dermatogical Drug Market Size and Forecast By Drug Type (2020 to 2031F) (In USD Billion)
Table 24: Colombia Dermatogical Drug Market Size and Forecast By Distribution channel (2020 to 2031F) (In USD Billion)
Table 25: Competitive Dashboard of top 5 players, 2025

Figure 1: South America Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 2: South America Dermatogical Drug Market Share By Country (2025)
Figure 3: Brazil Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: Argentina Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Colombia Dermatogical Drug Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Porter's Five Forces of Global Dermatogical Drug Market

Dermatological Drugs Market Research FAQs

The Brazilian Society of Dermatology reports that psoriasis affects approximately 1.3% of Brazil's population, with prevalence ranging from 0.9% to 1.1% in the Northern region to 1.9% in the South and Southeast.

ANVISA approved Winlevi (clascoterone) cream 1% for acne vulgaris in patients aged twelve years and older in 2025 and expanded regulatory frameworks for dermatological cannabis-based products.

ANMAT implemented Disposition 236/2026 establishing a simplified affidavit-based authorization system for imported medical products and cosmetics, eliminating expiration dates and reducing requirements.

Brazil's dermocosmetics market generated R$12.3 billion in the twelve months ending July 2025, representing 8.3% growth compared to the previous year.

Brazil's ANVISA has accelerated approvals for innovative therapies, Argentina's ANMAT has implemented sweeping import reforms, and Colombia's INVIMA has adopted a pro-competitive regulatory model through Resolution 2025029237.

Related Reports

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted